According to the Secretary of Health, the Release of the Tenth Package of Innovative Drugs, which consists of 34 new drug registrations, serves different therapeutic areas for the treatment of the main causes of mortality in Mexico. The list of conditions issued by the Federal Commission for the Protection against Sanitary Risk (Comisión Federal para la Protección contra Riesgos Sanitarios or Cofepris) includes diabetes, cardiac problems, pneumonia, chronic obstructive pulmonary disease (COPD), renal failure, different types of malignant tumors, and liver diseases.

José Narro Robles, head of the ministerial body, was accompanied by Julio Sánchez Tépoz (Cofepris authority) and Jesús Ancer Rodríguez (secretary of the General Health Council (Consejo de Salubridad General)) when the information was released to the public. In turn, the presidential Cabinet of Ministers official emphasized the fact that the government has already succeeded in introducing 310 new molecules since 2013 for the treatment of more than 70% of diseases.

In addition, the official qualified these new drugs as the result of a joint effort between the health authorities and the pharmaceutical industry within the framework of the Strategy to Promote Innovation. Already included in this instrument are five prescriptions for treating so-called orphan diseases (for ex.: metastatic melanoma, lymphoblastic leukemia, idiopathic pulmonary fibrosis, acute hepatic porphyria attacks, and acute hereditary angioedema attacks).

The Mexican Association of Industrial and Pharmaceutical Research (Asociación Mexicana de Industrias de Investigación Farmacéutica or AMIIF) and the National Chamber of the Pharmaceutical Industry (Cámara Nacional de la Industria Farmacéutica or Canifarma) are also part of this process. Both entities have aptly recognized the work of the health authorities and the minister, particularly with regard to the task of providing access to quality drugs and developing research at the national level.